Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26326285 | 0.78 | NPC1 (0.37) | HPGDHTTHSD17B10MEN1LMNA | |
| SCHEMBL23906476 | 0.76 | HTT (0.44) | HPGDHTTHSD17B10MEN1LMNA | |
| SCHEMBL26326281 | 0.68 | MAPT (0.37) | HTTLMNAKMT2APOLBMAPT | |
| SCHEMBL23903638 | 0.66 | PKMYT1 (0.43) | — | |
| SCHEMBL25685982 | 0.66 | HSD17B10 (0.46) | HPGDHTTHSD17B10MEN1LMNA | |
| SCHEMBL26083445 | 0.64 | NPC1 (0.39) | HPGDHTTHSD17B10MEN1LMNA | |
| SCHEMBL26326295 | 0.62 | NPC1 (0.40) | HPGDHTTHSD17B10MEN1LMNA | |
| SCHEMBL18673630 | 0.60 | ERN1 (0.64) | HPGDHTTHSD17B10MEN1LMNA | |
| SCHEMBL29956951 | 0.59 | FEN1 (0.45) | HPGDHTTMEN1LMNAKMT2A | |
| SCHEMBL23903087 | 0.59 | PKMYT1 (0.37) | MEN1KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | HPGD 996/4885HTT 2330/4885HSD17B10 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.